Boris Peaker
Stock Analyst at TD Cowen
(2.09)
# 2,656
Out of 4,829 analysts
20
Total ratings
36.36%
Success rate
9.73%
Average return
Main Sectors:
Stocks Rated by Boris Peaker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLYC GlycoMimetics | Downgrades: Hold | n/a | $0.26 | - | 1 | Jul 26, 2024 | |
| MGNX MacroGenics | Downgrades: Hold | n/a | $1.59 | - | 3 | May 10, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | $100 | $79.52 | +25.75% | 1 | Dec 4, 2023 | |
| ADCT ADC Therapeutics | Downgrades: Market Perform | n/a | $1.34 | - | 1 | Nov 9, 2023 | |
| PCRX Pacira BioSciences | Upgrades: Outperform | $50 | $25.09 | +99.28% | 1 | Aug 3, 2023 | |
| PCVX Vaxcyte | Initiates: Outperform | n/a | $31.59 | - | 1 | Apr 18, 2023 | |
| XNCR Xencor | Initiates: Outperform | n/a | $8.77 | - | 1 | Dec 6, 2022 | |
| EBS Emergent BioSolutions | Maintains: Market Perform | $30 → $29 | $5.84 | +396.58% | 1 | Sep 12, 2022 | |
| CTMX CytomX Therapeutics | Downgrades: Market Perform | n/a | $2.13 | - | 2 | Jul 11, 2022 | |
| NKTR Nektar Therapeutics | Downgrades: Market Perform | n/a | $0.71 | - | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.68 | - | 1 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $560.90 | - | 1 | Jun 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $95 → $102 | $80.43 | +26.82% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.04 | - | 1 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.37 | - | 1 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.87 | - | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.36 | - | 1 | Jul 24, 2017 |
GlycoMimetics
Jul 26, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.26
Upside: -
MacroGenics
May 10, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.59
Upside: -
Lantheus Holdings
Dec 4, 2023
Initiates: Outperform
Price Target: $100
Current: $79.52
Upside: +25.75%
ADC Therapeutics
Nov 9, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.34
Upside: -
Pacira BioSciences
Aug 3, 2023
Upgrades: Outperform
Price Target: $50
Current: $25.09
Upside: +99.28%
Vaxcyte
Apr 18, 2023
Initiates: Outperform
Price Target: n/a
Current: $31.59
Upside: -
Xencor
Dec 6, 2022
Initiates: Outperform
Price Target: n/a
Current: $8.77
Upside: -
Emergent BioSolutions
Sep 12, 2022
Maintains: Market Perform
Price Target: $30 → $29
Current: $5.84
Upside: +396.58%
CytomX Therapeutics
Jul 11, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.13
Upside: -
Nektar Therapeutics
Mar 15, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.71
Upside: -
Jul 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.68
Upside: -
Jun 12, 2017
Initiates: Outperform
Price Target: n/a
Current: $560.90
Upside: -
Jun 27, 2022
Maintains: Market Perform
Price Target: $95 → $102
Current: $80.43
Upside: +26.82%
Mar 3, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.04
Upside: -
Aug 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.37
Upside: -
Oct 22, 2018
Initiates: Outperform
Price Target: n/a
Current: $0.87
Upside: -
Jul 24, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.36
Upside: -